Suppr超能文献

联合抗逆转录病毒疗法治疗HIV-1相关微孢子虫病和隐孢子虫病。

Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy.

作者信息

Carr A, Marriott D, Field A, Vasak E, Cooper D A

机构信息

HIV Medicine Unit and Centre for Immunology, St Vincent's Hospital, Sydney, Australia.

出版信息

Lancet. 1998 Jan 24;351(9098):256-61. doi: 10.1016/S0140-6736(97)07529-6.

Abstract

BACKGROUND

Enterocytozoon bieneusi and Cryptosporidium parvum cause chronic antimicrobial-resistant gastrointestinal infections in HIV-1-infected individuals. HIV-1 reverse transcriptase inhibitors delay the onset of opportunistic infections, but are not known to reverse established infections. HIV-1 protease inhibitors are more effective across a broader range of HIV-1-infected immune cells. Combination antiretroviral therapy that includes a protease inhibitor could improve immunity to E bieneusi and C parvum.

METHODS

HIV-1 infected patients with chronic microsporidiosis (five), cryptosporidiosis (three), or dual infection (one), were treated with combination therapy that included at least one HIV-1 protease inhibitor. Outcome measures were symptoms, weight, use of antidiarrhoeal and antimicrobial drugs, T-lymphocyte subsets, HIV-1 viraemia, stool microscopy, and biopsy by endoscopy.

FINDINGS

All patients had complete clinical responses, gained a median 15 kg in weight, and ceased all antidiarrhoeal and antimicrobial therapies. Biliary cryptosporidiosis responded in both affected patients. Neither pathogen was detected in follow-up stool microscopy (eight of eight patients) or in biopsy samples by endoscopy (five of five). Intestinal architecture returned to normal in three patients. There was a dense CD8 lymphocyte and macrophage infiltrate and staining of intraepithelial E bieneusi with interferon-gamma before and after treatment, but little staining for CD4 or B lymphocytes, interleukin 10, or HIV-1 gp41. Five patients remained symptom-free after a median 13 months follow-up. Four patients had recurrent diarrhoea at 7-13 months (one with positive stool microscopy), associated with declining CD4 counts.

INTERPRETATION

Combination antiretroviral therapy that includes a protease inhibitor can restore immunity to E bieneusi or C parvum in HIV-1 infected individuals, and result in complete clinical, microbiological, and histological responses. The persistent CD8 cell and macrophage infiltrate, and the rapid time to relapse in patients with declining CD4 lymphocyte counts, suggest that neither infection was eradicated.

摘要

背景

微小隐孢子虫和贝氏等孢球虫可在HIV-1感染个体中引起慢性耐药性胃肠道感染。HIV-1逆转录酶抑制剂可延迟机会性感染的发生,但尚不清楚其能否逆转已有的感染。HIV-1蛋白酶抑制剂在更广泛的HIV-1感染免疫细胞中更有效。包含蛋白酶抑制剂的联合抗逆转录病毒疗法可能会改善对微小隐孢子虫和贝氏等孢球虫的免疫力。

方法

对患有慢性微孢子虫病(5例)、隐孢子虫病(3例)或双重感染(1例)的HIV-1感染患者采用包含至少一种HIV-1蛋白酶抑制剂的联合疗法进行治疗。观察指标包括症状、体重、止泻药和抗菌药物的使用情况、T淋巴细胞亚群、HIV-1病毒血症、粪便显微镜检查以及内镜活检。

研究结果

所有患者临床症状均完全缓解,体重中位数增加15千克,且停止了所有止泻和抗菌治疗。两名患有胆管隐孢子虫病的患者均有反应。在后续粪便显微镜检查(8例患者中的8例)或内镜活检样本(5例患者中的5例)中均未检测到这两种病原体。3例患者的肠道结构恢复正常。治疗前后,上皮内微小隐孢子虫均有密集的CD8淋巴细胞和巨噬细胞浸润以及干扰素-γ染色,但CD4或B淋巴细胞、白细胞介素10或HIV-1 gp41染色较少。5例患者在中位数为13个月的随访后仍无症状。4例患者在7至13个月时出现复发性腹泻(1例粪便显微镜检查呈阳性),与CD4计数下降有关。

解读

包含蛋白酶抑制剂的联合抗逆转录病毒疗法可恢复HIV-1感染个体对微小隐孢子虫或贝氏等孢球虫的免疫力,并导致完全的临床、微生物学和组织学反应。持续存在的CD8细胞和巨噬细胞浸润,以及CD4淋巴细胞计数下降患者的快速复发时间,表明这两种感染均未被根除。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验